Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer

Yasoo Sugiura, Hiroyuki Fujimoto, Munehiro Yamamoto, Hisashi Nomura, Toshinori Hashizume, Osamu Kawai, Norito Araki, Kotaro Kawakami, Hitoshi Sueki, Hisae Fusegawa, Yasuyuki Ohkubo, Etsuo Nemoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-related adverse events. Case presentation: A 66-year-old man without any history of autoimmune disease was referred to our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage IDA non-small-cell lung cancer by using bronchoscopic biopsy, computed tomography, and FDG-PET. After a single course of cisplatin and pemetrexed, the tumor size increased remarkably and the regimen was changed to nivolumab (3mg/kg every 2 weeks). Psoriasis and psoriatic arthritis were observed after 4 courses of nivolumab. Nivolumab treatment continued, and the oral administration of prednisolone (20 mg/day) could improve psoriasis and psoriatic arthritis. However, the lung cancer showed progressive disease after the 11th course of nivolumab. Conclusion: Psoriasis and psoriatic arthritis were induced by nivolumab in the patient without any history of autoimmune disease. It is unclear how prednisolone affected nivolumab for the treatment of lung cancer.

Original languageEnglish
Pages (from-to)787-789
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume44
Issue number9
Publication statusPublished - 2017 Sep 1

Fingerprint

Psoriatic Arthritis
Psoriasis
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Prednisolone
Autoimmune Diseases
Pemetrexed
Blocking Antibodies
Cisplatin
Oral Administration
nivolumab
Neoplasms
Therapeutics
Tomography
Biopsy

Keywords

  • Lung cancer
  • Nivolumab
  • Prednisolone
  • Psoriasis and psoriatic arthritis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sugiura, Y., Fujimoto, H., Yamamoto, M., Nomura, H., Hashizume, T., Kawai, O., ... Nemoto, E. (2017). Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer. Japanese Journal of Cancer and Chemotherapy, 44(9), 787-789.

Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer. / Sugiura, Yasoo; Fujimoto, Hiroyuki; Yamamoto, Munehiro; Nomura, Hisashi; Hashizume, Toshinori; Kawai, Osamu; Araki, Norito; Kawakami, Kotaro; Sueki, Hitoshi; Fusegawa, Hisae; Ohkubo, Yasuyuki; Nemoto, Etsuo.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 44, No. 9, 01.09.2017, p. 787-789.

Research output: Contribution to journalArticle

Sugiura, Y, Fujimoto, H, Yamamoto, M, Nomura, H, Hashizume, T, Kawai, O, Araki, N, Kawakami, K, Sueki, H, Fusegawa, H, Ohkubo, Y & Nemoto, E 2017, 'Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer', Japanese Journal of Cancer and Chemotherapy, vol. 44, no. 9, pp. 787-789.
Sugiura, Yasoo ; Fujimoto, Hiroyuki ; Yamamoto, Munehiro ; Nomura, Hisashi ; Hashizume, Toshinori ; Kawai, Osamu ; Araki, Norito ; Kawakami, Kotaro ; Sueki, Hitoshi ; Fusegawa, Hisae ; Ohkubo, Yasuyuki ; Nemoto, Etsuo. / Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer. In: Japanese Journal of Cancer and Chemotherapy. 2017 ; Vol. 44, No. 9. pp. 787-789.
@article{731371fdff2945b2b37d821b8de2f968,
title = "Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer",
abstract = "Background: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-related adverse events. Case presentation: A 66-year-old man without any history of autoimmune disease was referred to our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage IDA non-small-cell lung cancer by using bronchoscopic biopsy, computed tomography, and FDG-PET. After a single course of cisplatin and pemetrexed, the tumor size increased remarkably and the regimen was changed to nivolumab (3mg/kg every 2 weeks). Psoriasis and psoriatic arthritis were observed after 4 courses of nivolumab. Nivolumab treatment continued, and the oral administration of prednisolone (20 mg/day) could improve psoriasis and psoriatic arthritis. However, the lung cancer showed progressive disease after the 11th course of nivolumab. Conclusion: Psoriasis and psoriatic arthritis were induced by nivolumab in the patient without any history of autoimmune disease. It is unclear how prednisolone affected nivolumab for the treatment of lung cancer.",
keywords = "Lung cancer, Nivolumab, Prednisolone, Psoriasis and psoriatic arthritis",
author = "Yasoo Sugiura and Hiroyuki Fujimoto and Munehiro Yamamoto and Hisashi Nomura and Toshinori Hashizume and Osamu Kawai and Norito Araki and Kotaro Kawakami and Hitoshi Sueki and Hisae Fusegawa and Yasuyuki Ohkubo and Etsuo Nemoto",
year = "2017",
month = "9",
day = "1",
language = "English",
volume = "44",
pages = "787--789",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "9",

}

TY - JOUR

T1 - Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced non-small-cell lung cancer

AU - Sugiura, Yasoo

AU - Fujimoto, Hiroyuki

AU - Yamamoto, Munehiro

AU - Nomura, Hisashi

AU - Hashizume, Toshinori

AU - Kawai, Osamu

AU - Araki, Norito

AU - Kawakami, Kotaro

AU - Sueki, Hitoshi

AU - Fusegawa, Hisae

AU - Ohkubo, Yasuyuki

AU - Nemoto, Etsuo

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-related adverse events. Case presentation: A 66-year-old man without any history of autoimmune disease was referred to our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage IDA non-small-cell lung cancer by using bronchoscopic biopsy, computed tomography, and FDG-PET. After a single course of cisplatin and pemetrexed, the tumor size increased remarkably and the regimen was changed to nivolumab (3mg/kg every 2 weeks). Psoriasis and psoriatic arthritis were observed after 4 courses of nivolumab. Nivolumab treatment continued, and the oral administration of prednisolone (20 mg/day) could improve psoriasis and psoriatic arthritis. However, the lung cancer showed progressive disease after the 11th course of nivolumab. Conclusion: Psoriasis and psoriatic arthritis were induced by nivolumab in the patient without any history of autoimmune disease. It is unclear how prednisolone affected nivolumab for the treatment of lung cancer.

AB - Background: Immune checkpoint-blocking antibodies may induce specific side effects known as immune-related adverse events. Case presentation: A 66-year-old man without any history of autoimmune disease was referred to our hospital for treatment of lung cancer in the right upper lobe. The tumor was diagnosed as Stage IDA non-small-cell lung cancer by using bronchoscopic biopsy, computed tomography, and FDG-PET. After a single course of cisplatin and pemetrexed, the tumor size increased remarkably and the regimen was changed to nivolumab (3mg/kg every 2 weeks). Psoriasis and psoriatic arthritis were observed after 4 courses of nivolumab. Nivolumab treatment continued, and the oral administration of prednisolone (20 mg/day) could improve psoriasis and psoriatic arthritis. However, the lung cancer showed progressive disease after the 11th course of nivolumab. Conclusion: Psoriasis and psoriatic arthritis were induced by nivolumab in the patient without any history of autoimmune disease. It is unclear how prednisolone affected nivolumab for the treatment of lung cancer.

KW - Lung cancer

KW - Nivolumab

KW - Prednisolone

KW - Psoriasis and psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=85037640146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037640146&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 787

EP - 789

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 9

ER -